Comment on: “Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS”

Abstract

Referring to the publication by Maev et al. [1], it can be agreed with the authors that particle size, label claim-compliant lipase activity, high batch-to-batch conformity, gastric resistance and quick enzyme release in the intestine are relevant parameters for successful treatment of pancreatic exocrine insufficiency with pancreatic enzyme-replacement therapy (PERT). However, the authors' claim that the particle size of PERT should be smaller than 2 mm appears debatable, and it should be emphasized that particle size distribution (PSD) is also relevant.

Author’s Reply to Petersen: “Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS”

“…Referring to the Letter to the Editor by Prof. Dr. Karl-Uwe Petersen [1] regarding our article entitled Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS [2], we would like to provide further information and feedback.…”